JP2016534996A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016534996A5 JP2016534996A5 JP2016523209A JP2016523209A JP2016534996A5 JP 2016534996 A5 JP2016534996 A5 JP 2016534996A5 JP 2016523209 A JP2016523209 A JP 2016523209A JP 2016523209 A JP2016523209 A JP 2016523209A JP 2016534996 A5 JP2016534996 A5 JP 2016534996A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- administration
- antigen
- binding fragment
- copd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 21
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 9
- 210000003979 eosinophil Anatomy 0.000 claims 7
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 6
- 229950000321 benralizumab Drugs 0.000 claims 4
- 101100384805 Homo sapiens ARCN1 gene Proteins 0.000 claims 3
- 230000005713 exacerbation Effects 0.000 claims 3
- 229940125389 long-acting beta agonist Drugs 0.000 claims 3
- 229940110339 Long-acting muscarinic antagonist Drugs 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361891175P | 2013-10-15 | 2013-10-15 | |
| US61/891,175 | 2013-10-15 | ||
| US201461970126P | 2014-03-25 | 2014-03-25 | |
| US61/970,126 | 2014-03-25 | ||
| PCT/US2014/060432 WO2015057668A1 (en) | 2013-10-15 | 2014-10-14 | Methods for treating chronic obstructive pulmonary disease using benralizumab |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019132432A Division JP6870037B2 (ja) | 2013-10-15 | 2019-07-18 | ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016534996A JP2016534996A (ja) | 2016-11-10 |
| JP2016534996A5 true JP2016534996A5 (cg-RX-API-DMAC7.html) | 2017-11-16 |
Family
ID=52809872
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016523209A Pending JP2016534996A (ja) | 2013-10-15 | 2014-10-14 | ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法 |
| JP2019132432A Active JP6870037B2 (ja) | 2013-10-15 | 2019-07-18 | ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法 |
| JP2021068065A Pending JP2021107421A (ja) | 2013-10-15 | 2021-04-14 | ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019132432A Active JP6870037B2 (ja) | 2013-10-15 | 2019-07-18 | ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法 |
| JP2021068065A Pending JP2021107421A (ja) | 2013-10-15 | 2021-04-14 | ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法 |
Country Status (12)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105164157B (zh) | 2013-04-29 | 2024-05-28 | 豪夫迈·罗氏有限公司 | Fc-受体结合的修饰的非对称抗体及使用方法 |
| CN110981957B (zh) | 2014-01-15 | 2024-12-24 | 豪夫迈·罗氏有限公司 | 具有改善的蛋白A结合作用的Fc区变体 |
| AU2016272399B2 (en) | 2015-06-01 | 2021-09-09 | Kyowa Kirin Co., Ltd. | Therapeutic agent and therapeutic method for pulmonary hypertension |
| CN109544378B (zh) * | 2018-10-27 | 2024-06-25 | 平安医疗健康管理股份有限公司 | 一种肺源性心脏病资质认证方法、设备及服务器 |
| TW202110479A (zh) * | 2019-05-16 | 2021-03-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法 |
| JP7696900B2 (ja) * | 2019-12-06 | 2025-06-23 | サノフィ・バイオテクノロジー | Ｉｌ－３３アンタゴニストを投与することによりｃｏｐｄを治療するための方法 |
| EP3957308A1 (en) * | 2020-08-21 | 2022-02-23 | Palobiofarma, S.L. | (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases |
| WO2023034993A1 (en) * | 2021-09-03 | 2023-03-09 | Gleich Gerald J | Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1241944C (zh) | 1995-09-11 | 2006-02-15 | 协和发酵工业株式会社 | 抗人白介素－5受体α链的抗体 |
| PT1176195E (pt) * | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| AU2001232304A1 (en) * | 2000-02-15 | 2001-08-27 | Kyowa Hakko Kogyo Co. Ltd. | Eosinophil-specific apoptosis inducer |
| US6946292B2 (en) * | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US8093357B2 (en) * | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20060014680A1 (en) * | 2004-07-13 | 2006-01-19 | Caiding Xu | Peptides and compounds that bind to the IL-5 receptor |
| US20100291073A1 (en) * | 2007-05-14 | 2010-11-18 | Medimmune, Llc | Methods of reducing eosinophil levels |
| CN101249093A (zh) * | 2008-03-19 | 2008-08-27 | 李虎山 | 一种治疗慢性阻塞性肺部疾病的组合物 |
| RU2013122123A (ru) * | 2010-10-15 | 2014-11-20 | Медиммьюн Лимитед | Терапевтические средства для улучшения легочной функции |
| EP2652498B1 (en) * | 2010-12-16 | 2018-04-18 | F.Hoffmann-La Roche Ag | Diagnosis and treatments relating to th2 inhibition |
| US8961965B2 (en) * | 2011-05-18 | 2015-02-24 | Medimmune, Llc | Methods of diagnosing and treating pulmonary diseases or disorders |
| CN104039352A (zh) * | 2011-11-01 | 2014-09-10 | 米迪缪尼有限公司 | 用于降低哮喘急性恶化的频率和严重性的方法 |
| SG11201600484TA (en) * | 2013-08-12 | 2016-02-26 | Medimmune Llc | Methods for improving asthma symptoms using benralizumab |
| HUE042607T2 (hu) * | 2013-08-12 | 2019-07-29 | Astrazeneca Ab | Eljárások asztma exacerbációs gyakoriságának csökkentésére benralizumab alkalmazásával |
| CN111588849A (zh) * | 2013-08-12 | 2020-08-28 | 阿斯特拉捷利康股份公司 | 使用贝那利珠单抗增加哮喘患者用力呼气量的方法 |
-
2014
- 2014-10-14 CN CN201480056549.0A patent/CN105636607A/zh active Pending
- 2014-10-14 AU AU2014334563A patent/AU2014334563A1/en not_active Abandoned
- 2014-10-14 US US14/513,866 patent/US20150104447A1/en not_active Abandoned
- 2014-10-14 EP EP14853201.3A patent/EP3057609A4/en not_active Withdrawn
- 2014-10-14 MX MX2016004329A patent/MX2016004329A/es unknown
- 2014-10-14 CA CA2925402A patent/CA2925402A1/en not_active Abandoned
- 2014-10-14 CN CN202110508239.XA patent/CN113230399A/zh active Pending
- 2014-10-14 RU RU2016118425A patent/RU2706729C2/ru active
- 2014-10-14 SG SG10201807318RA patent/SG10201807318RA/en unknown
- 2014-10-14 EP EP18189626.7A patent/EP3485902A1/en not_active Withdrawn
- 2014-10-14 SG SG11201601807XA patent/SG11201601807XA/en unknown
- 2014-10-14 KR KR1020167009675A patent/KR20160061352A/ko not_active Ceased
- 2014-10-14 BR BR112016008082A patent/BR112016008082A2/pt not_active Application Discontinuation
- 2014-10-14 WO PCT/US2014/060432 patent/WO2015057668A1/en not_active Ceased
- 2014-10-14 JP JP2016523209A patent/JP2016534996A/ja active Pending
-
2016
- 2016-04-04 MX MX2019013468A patent/MX2019013468A/es unknown
- 2016-05-31 US US15/168,711 patent/US20170107291A1/en not_active Abandoned
-
2017
- 2017-11-29 US US15/825,526 patent/US20180291108A1/en not_active Abandoned
-
2019
- 2019-05-24 US US16/422,212 patent/US20200123262A1/en not_active Abandoned
- 2019-07-18 JP JP2019132432A patent/JP6870037B2/ja active Active
-
2020
- 2020-04-02 AU AU2020202333A patent/AU2020202333A1/en not_active Abandoned
-
2021
- 2021-04-14 JP JP2021068065A patent/JP2021107421A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016534996A5 (cg-RX-API-DMAC7.html) | ||
| Lugogo et al. | Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study | |
| Thibodeaux et al. | A review of dupilumab in the treatment of atopic diseases | |
| Mukherjee et al. | Anti-IL5 therapy for asthma and beyond | |
| Dahl et al. | Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study | |
| Wedzicha et al. | Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients | |
| Fala | Ofev (Nintedanib): first tyrosine kinase inhibitor approved for the treatment of patients with idiopathic pulmonary fibrosis | |
| JP2016513640A5 (cg-RX-API-DMAC7.html) | ||
| JP2016515124A5 (cg-RX-API-DMAC7.html) | ||
| D'Urzo et al. | A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease | |
| Mkorombindo et al. | Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease | |
| CA2918105A1 (en) | Methods for reducing exacerbation rates of asthma using benralizumab | |
| Saco et al. | Benralizumab for the treatment of asthma | |
| Hanania et al. | Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD | |
| Donohue et al. | One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD | |
| Sadigursky et al. | Effect of tranexamic acid on bleeding control in total knee arthroplasty | |
| JP2014520874A5 (cg-RX-API-DMAC7.html) | ||
| JP2014513121A5 (cg-RX-API-DMAC7.html) | ||
| RU2015127834A (ru) | Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина | |
| Mathioudakis et al. | Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: are they equivalent? | |
| JP2013525310A5 (cg-RX-API-DMAC7.html) | ||
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| JP2017514829A5 (cg-RX-API-DMAC7.html) | ||
| Black et al. | Interventions to reduce the frequency of exacerbations of chronic obstructive pulmonary disease | |
| RU2013126798A (ru) | Комбинированная терапия дексаметазоном |